Basel Medical Group Net Income
| BMGL Stock | 0.63 0.02 3.28% |
As of the 13th of February 2026, Basel Medical shows the Mean Deviation of 5.31, risk adjusted performance of (0.09), and Standard Deviation of 7.73. Basel Medical Group technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Basel Medical Group information ratio and potential upside to decide if Basel Medical Group is priced correctly, providing market reflects its regular price of 0.63 per share. As Basel Medical Group is a penny stock we also strongly suggest to validate its jensen alpha numbers.
Basel Medical Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.3201 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -10.9 M | -10.3 M | |
| Net Loss | -11.3 M | -10.7 M | |
| Net Income Per Share | 0.10 | 0.08 | |
| Net Income Per E B T | 0.87 | 0.70 |
Basel | Net Income | Build AI portfolio with Basel Stock |
Historical Net Income data for Basel Medical serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Basel Medical Group represents a compelling investment opportunity.
Latest Basel Medical's Net Income Growth Pattern
Below is the plot of the Net Income of Basel Medical Group over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Basel Medical Group financial statement analysis. It represents the amount of money remaining after all of Basel Medical Group operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Basel Medical's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Basel Medical's overall financial position and show how it may be relating to other accounts over time.
| Net Income | 10 Years Trend |
|
Net Income |
| Timeline |
Basel Net Income Regression Statistics
| Arithmetic Mean | (335,864) | |
| Coefficient Of Variation | (1,532) | |
| Mean Deviation | 3,799,265 | |
| Median | 1,977,964 | |
| Standard Deviation | 5,146,459 | |
| Sample Variance | 26.5T | |
| Range | 14.2M | |
| R-Value | (0.66) | |
| Mean Square Error | 16.1T | |
| R-Squared | 0.43 | |
| Significance | 0 | |
| Slope | (669,604) | |
| Total Sum of Squares | 423.8T |
Basel Net Income History
Other Fundumenentals of Basel Medical Group
Basel Medical Net Income component correlations
Basel Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Basel Medical is extremely important. It helps to project a fair market value of Basel Stock properly, considering its historical fundamentals such as Net Income. Since Basel Medical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Basel Medical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Basel Medical's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Basel Medical. Projected growth potential of Basel fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Basel Medical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.51) | Revenue Per Share | Quarterly Revenue Growth 0.322 | Return On Assets | Return On Equity |
Investors evaluate Basel Medical Group using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Basel Medical's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Basel Medical's market price to deviate significantly from intrinsic value.
It's important to distinguish between Basel Medical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Basel Medical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Basel Medical's market price signifies the transaction level at which participants voluntarily complete trades.
Basel Medical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Basel Medical's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Basel Medical.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Basel Medical on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Basel Medical Group or generate 0.0% return on investment in Basel Medical over 90 days. Basel Medical is related to or competes with P3 Health, Vicarious Surgical, Longduoduo Company, Precipio, IBio Common, Nutriband, and Iterum Therapeutics. Basel Medical is entity of United States More
Basel Medical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Basel Medical's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Basel Medical Group upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 50.69 | |||
| Value At Risk | (12.38) | |||
| Potential Upside | 13.92 |
Basel Medical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Basel Medical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Basel Medical's standard deviation. In reality, there are many statistical measures that can use Basel Medical historical prices to predict the future Basel Medical's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (1.07) | |||
| Total Risk Alpha | (1.56) | |||
| Treynor Ratio | (0.74) |
Basel Medical February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.73) | |||
| Mean Deviation | 5.31 | |||
| Coefficient Of Variation | (791.00) | |||
| Standard Deviation | 7.73 | |||
| Variance | 59.73 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (1.07) | |||
| Total Risk Alpha | (1.56) | |||
| Treynor Ratio | (0.74) | |||
| Maximum Drawdown | 50.69 | |||
| Value At Risk | (12.38) | |||
| Potential Upside | 13.92 | |||
| Skewness | 0.8895 | |||
| Kurtosis | 3.62 |
Basel Medical Group Backtested Returns
Basel Medical Group secures Sharpe Ratio (or Efficiency) of -0.0792, which signifies that the company had a -0.0792 % return per unit of risk over the last 3 months. Basel Medical Group exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Basel Medical's Mean Deviation of 5.31, risk adjusted performance of (0.09), and Standard Deviation of 7.73 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.33, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Basel Medical will likely underperform. At this point, Basel Medical Group has a negative expected return of -0.63%. Please make sure to confirm Basel Medical's potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if Basel Medical Group performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.11 |
Insignificant reverse predictability
Basel Medical Group has insignificant reverse predictability. Overlapping area represents the amount of predictability between Basel Medical time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Basel Medical Group price movement. The serial correlation of -0.11 indicates that less than 11.0% of current Basel Medical price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.11 | |
| Spearman Rank Test | -0.18 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Basel Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Basel Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Basel Medical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Basel Medical could also be used in its relative valuation, which is a method of valuing Basel Medical by comparing valuation metrics of similar companies.Basel Medical is currently under evaluation in net income category among its peers.
Basel Fundamentals
| Return On Equity | -1.95 | ||||
| Return On Asset | -0.0467 | ||||
| Profit Margin | (1.00) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 11.81 M | ||||
| Shares Outstanding | 18.79 M | ||||
| Shares Owned By Insiders | 54.32 % | ||||
| Shares Owned By Institutions | 1.61 % | ||||
| Number Of Shares Shorted | 132.12 K | ||||
| Price To Book | 2.98 X | ||||
| Price To Sales | 0.95 X | ||||
| Revenue | 12.11 M | ||||
| Gross Profit | 3.18 M | ||||
| EBITDA | (1.13 M) | ||||
| Total Debt | 3.42 M | ||||
| Book Value Per Share | 0.21 X | ||||
| Short Ratio | 2.36 X | ||||
| Earnings Per Share | (0.51) X | ||||
| Number Of Employees | 82 | ||||
| Market Capitalization | 11.46 M | ||||
| Total Asset | 16.85 M | ||||
| Retained Earnings | (4.4 M) | ||||
| Working Capital | 2.43 M | ||||
| Net Asset | 16.85 M |
About Basel Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Basel Medical Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Basel Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Basel Medical Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Basel Medical. Projected growth potential of Basel fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Basel Medical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.51) | Revenue Per Share | Quarterly Revenue Growth 0.322 | Return On Assets | Return On Equity |
Investors evaluate Basel Medical Group using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Basel Medical's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Basel Medical's market price to deviate significantly from intrinsic value.
It's important to distinguish between Basel Medical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Basel Medical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Basel Medical's market price signifies the transaction level at which participants voluntarily complete trades.